Pioneering Botanical Therapies for Inflammatory and Neurological Diseases

Investor Summary | 2025

Transforming the $1.6 Trillion Pharma Industry with Polyphenol-Based Drug Innovation

Canurta Therapeutics is pioneering a new era in botanical medicine. We develop novel drugs from rare cannabis-derived polyphenols—such as Cannflavin A & B—to address inflammatory and neurological conditions, beginning with ALS.

Led by a seasoned team in cannabinoid science and clinical development, our pipeline includes trial-ready and preclinical assets backed by global IP, regulatory momentum, and a transformative approach to drug discovery.

Why Invest

Innovative Pipeline

CNR-401 leads a growing pipeline targeting ALS, Alzheimer’s, and inflammation—built on multi-pathway compounds and validated preclinical data.

Breakthrough Compounds

Cannflavins A & B—30x stronger than aspirin—are exclusive to Canurta.

Regulatory & Market Traction

Orphan Drug paths in the U.S. and EU, with global entry points in Australia, Canada, Brazil and Germany.

AI-Driven Drug Development

PolyKye™ accelerates adaptive, multi-target drug development and enables precision across a scalable pipeline.

Proven Leadership

Veterans from GW Pharma—the only company to have an FDA-approved cannabis-based drug.

Early Revenue

ALS programs launch in 2025 with multi-year agreements totaling up to $67M across Brazil and Germany.

Pioneers in Botanical Therapeutics

Canurta Day Video Series Email Image.jpg

Founded in 2021, Canurta develops polyphenol-based drugs for neurological and inflammatory conditions. Our lead candidate, CNR-401, enters ALS trials in 2025 with early commercial programs in Brazil and Germany. Backed by over $11M in capital and $2.77M in non-dilutive funding, global IP, and GMP infrastructure, we are bridging nature with next-generation medicine.

Innovating Neurodegenerative Care with Nature

Harnessing Nature's Rarest Polyphenols

Cannflavins A (CFA) & B (CFB) are rare cannabis-derived polyphenols with potent anti-inflammatory and neuroprotective effects. Preclinical studies show they’re 30 times more effective and safer than Aspirin with a safer profile, targeting key proinflammatory enzymes (mPGES-1, 5-LO) and regulating neuroprotective enzymes like MAGL and FAAH. These compounds offer a groundbreaking approach to treating chronic inflammation and neurodegeneration.

Milestones and Growth

$10M

Raised in capital and non-dilutive funding with a clinical ready candidate.

23

Filed patents in 7 major markets, covering novel extraction, biosynthesis, and activation production methods, therapeutic compositions, and AI-driven drug discovery.

8

Expert team members with a world-class advisory board, including key members from GW Pharma.

Neurodegenerative Complexity

By 2050, the number of people living with neurodegenerative diseases is expected to increase by nearly 60%.

Chronic Inflammation

Current therapies provide limited symptom relief, minimal neuroprotection, and often cause side effects. Botanicals may offer safer alternatives with fewer risks.

Complex Dynamics

Neurodegenerative diseases progress rapidly due to multifactorial dynamics. Modern approaches require therapies that can target multiple pathways.

Treatment Limitations

Current therapies provide limited symptom relief, minimal neuroprotection, and often cause side effects. Botanicals may offer safer alternatives with fewer risks.

Lead Candidate CNR-401

CNR-401 is a small molecule NCE composed of multiple bioactive compounds, including cannflavin A. Its multi-mechanistic approach targets neuroinflammation, oxidative stress, and excitotoxicity, offering both symptom relief and potential lifespan extension in neurodegenerative diseases like ALS and Alzheimer’s.

Developed as an Orphan Drug and derived from Cannabis sativa, CNR-401 follows a de-risked regulatory path, leveraging precedents set by globally approved cannabinoid-based drugs such as Sativex, Marinol, and Epidiolex.

CNR-401: Neurodegenerative Care | Canurta Therapeutics

CBD

Other Minor Cannabinoids

Terpenoids

CFA

Enhanced Motor Activity: At 2 μM, CNR-401 restored 85% of normal motility in a BMAA-induced zebrafish model, outperforming Edaravone, the standard ALS treatment, with confirmed non-toxicity at therapeutic doses.

Anxiolytic Activity: CNR-401’s anxiolytic properties showed it rescued 80% of zebrafish from anxiety-like behavior in a thigmotaxis study, with effects comparable to CBD. These findings highlight its neuroprotective and symptomatic benefits for ALS.

Superior Gene Modulation: RNA sequencing of BMAA-induced zebrafish model showed CNR-401 significantly modulated NOS2 (motor neuron degeneration) and DOCK2 (ALS hub gene), outperforming Edaravone in targeting neuronal function pathways and reducing neuroinflammatory and apoptotic markers.

Mechanisms of Action

CNR-401's unique formulation targets key processes like inflammation, neuroprotection, and muscle control, offering therapeutic benefits across multiple pathways to address the complex mechanisms of diseases like ALS.

Neuron Survival and Disease Progression:

Symptoms: Neuroinflammation, motor neuron degeneration, excitotoxicity, cell death

Therapeutic Benefits: Anti-Inflammatory, Neuroprotective, Glutamate Modulation, Antiseizure, Anti-Apoptotic, Microglial Regulation

MOA: CBs: CB1, CB2, GPR55, PRARy | TPs: NMDA, NF-kB, iNOS | CFA: PGE2, 5-LO

Bulbar Function:

Symptoms: Dysarthria, Dysphagia, Sialorrhea

Therapeutic Benefits: Endocannabinoid System Modulation, Neuroprotective, Anti-inflammatory

MOA: CBs: CB1, CB2, 5-HT1A, PPARγ | TPs: NMDA, Glutamate Receptors, TRP Channels | CFA: Amyloid-beta

Respiratory Function:

Symptoms: Dyspnea, Orthopnea, respiratory muscle weakness, mucus buildup

Therapeutic Benefits: Anti-Inflammatory, Bronchodilator, Pulmonary Support

MOA: CBs: CB1, CB2, A2A Receptors | TPs: iNOS, MAPK, NF-kB | CFA: PenH, EF50

Metabolism and Nutrition:

Symptoms: Cachexia, appetite loss, nausea, GI distress, malnutrition

Therapeutic Benefits: Appetite Stimulation, Anti-emetic

MOA: CBs: CB1, CB2, 5-HT1A, TRPV, histamine H3 | TPs: FAAH, MAGL, A2A | CFA: ECS Modulation

Motor and Muscle Support:

Symptoms: Weakness, spasticity, cramps, fine motor impairment, mobility loss

Therapeutic Benefits: Anti-Inflammatory, Analgesic, Antispasmodic, Endocannabinoid Modulation

MOA: CBs: CB1, CB2, TRPV, 5-HT1A | TPs: COX-2, Potassium and Cholinergic Receptors | CFA:PGE2, 5-LO

Oxidative Stress and Cellular Support:

Symptoms: Mitochondrial dysfunction, oxidative stress, neurodegeneration, energy deficits

Therapeutic Benefits: Antioxidant, Mitochondrial Protection, Autophagy

and Proteostasis

MOA: CBs: Nrf2/HO-1, SOD, catalase, Bcl-2 | TPs: A2A, GABA | CFA: Amyloid-beta, senescent cells

Psychological and Emotional Well-Being:

Symptoms: Anxiety, depression, cognitive dysfunction, sleep disturbances

Therapeutic Benefits: Anxiolytic, Mood Enhancing

MOA: CBs: CB1, CB2, 5-HT1A, PPARγ | TPs: A2A, GABA | CFA: Thigmotaxis Modulation

Vast Market Potential

With the neurodegenerative disease market projected at $60.1B, CNR-401 serves as a strategic entry point in ALS with strong potential to expand into additional indications—addressing critical unmet needs across a high-growth sector.

$969M ALS Market: Projected by 2028.

Orphan Designation Exclusivity: 7 years in the US and 10 in the EU, granting market dominance.

Only Two FDA-Approved Botanical Drugs: Highlighting an untapped market.

Neurodegenerative pipeline-in-a-product: Potential for blockbuster status across multiple conditions.

Projected Neurodegenerative Disease Market

Current Treatment Limitations

Radicava (Edaravone)

$185,000/year

Limited to neuroprotection
Modest efficacy
No symptom relief

Riluzole

$5,403/year

Limited to neuroprotection
Modest efficacy
No symptom relief

Sativex

$7,822/year

Limited to spasticity and pain
No neuroprotection
Not approved in ALS

Go-to-Market Strategy

Affordable Pricing

CNR-401 offers comprehensive ALS symptom relief and neuroprotection at a fraction of the cost of Edaravone, with broader benefits than Riluzole and a modest premium over Sativex.

Minimum $19,555/year

Early Market Entry

CNR-401 will enter Brazil and Germany through a phased commercialization strategy, supported by strong reimbursement pathways and Real-World Evidence to fuel expansion into broader neurodegenerative markets.

Brazil and Germany

Phase II Human Trials

In parallel, Phase II trials in Australia will generate data to inform future Confirmatory Trials, supporting global expansion and reimbursement pathways.

Accelerated Development

Revenue Projections

Early revenue targets are met in 2025 through Brazil and Germany, generating $977K from ALS patients. Revenue scales to $31.7M in 2026 with expanded access. Profitability is achieved in 2027, and by 2028, revenue grows to $462.7M, supported by global market entry and orphan label extensions into Alzheimer’s and other neurodegenerative diseases. ODD exclusivity secures 7–10 years of market protection in the US and EU.

We are raising $10M in our Pre-Seed round

Canurta’s CAD 10M pre-seed gives early investors a first-mover advantage in the growing neurodegenerative market, combining proprietary technology with novel small molecule therapies. Backed by government and anchor funding, risks are reduced, and key milestones—including clinical trials and a 2025 TSX-V listing—pave the way for strong returns and a lucrative exit.

Upcoming Milestones

Trial Launch (Q2 - Q3 2025)

TGA filing for HALOS trial approval, with first patient dosing anticipated within two months.

Capital and Public Market Strategy (Q2 - Q4 2025)

Share Subscription facility secured (Feb), with RTO & convertible note offering (Sept–Nov).

FDA Engagement and ODD (Q1 2025)

Type B & C meetings and feedback on CNR-401 development plan and roadmap. ODD submitted.

Commercial Entry (Q3 2025)

Early revenue through Brazilian ALS clinic collaboration & distribution agreement, alongside German supply chain setup.

Lucrative Exit Potential

Early revenue targets are hit in 2025 with $977K from ALS patients. This scales to $31.7M by 2026 as the market expands. Profitability is reached in 2027, and by 2028, revenue grows to $462.7M, with ongoing expansion into key global markets.

Canurta Therapeutics

Credible Science Team

Robust Clinical Pipeline

Blockbuster Potential

Novel Cannabis Molecules

AI & Bioinformatics Platform

GW Pharmaceuticals

Credible Science Team

Robust Clinical Pipeline

Blockbuster Potential

Key Metrics
Annual Cost	~30K CAD (NA)
IP & Exclusivity	Global patents + 7-10 yrs exclusivity
Regulatory Path	Botanical + Orphan
Mechanism	Multi-target
Symptom Relief	Broad
Disease Modification	Strong Potential
Safety Profile	Oral, favorable

Ecosystem Partners

Partnered for Success

Canurta expands its offerings, capabilities and resources through strategic partnerships with various organizations and government programs, enhancing resource efficiency through diverse support structures.